Following NCCN guidelines for metastatic breast cancer results in lower costs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Direct cost for metastatic breast cancer patients increases dramatically when their treatment differs from recommendations in the NCCN Clinical Practice Guidelines in Oncology.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Vinay Prasad, a MAHA-aligned hematologist-oncologist with an avid cyber following, was named director of the FDA Center for Biologics Evaluation and Research, where he will be responsible for the agency’s regulation of vaccines and biologics, including cell and gene therapies.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login